secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATAI Life Sciences N.V. (—)
CIK:        0001840904
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001140361-24-015908
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atai Life Sciences reports Q4 2023 net loss $18.3M, cash $154.2M; BPL-003 Phase 2a shows 45% remission at 3 months
--------------------------------------------------------------------------------

- Net loss for Q4 2023 was $18.3M vs $45.0M in Q4 2022; full-year net loss $40.2M vs $152.4M.
- Cash and short-term investments $154.2M as of Dec 31, 2023, down from $273.1M a year ago.
- R&D expenses decreased to $62.2M for FY 2023 from $74.3M; G&A expenses decreased to $63.6M from $70.4M.
- Strategic investment in Beckley Psytech (Jan 2024) added BPL-003 and ELE-101; Phase 2b BPL-003 results expected 2H 2024.
- VLS-01 Phase 1b dosing initiated; COMP360 Phase 3 top-line data expected Q4 2024 and mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124015908/0001140361-24-015908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124015908/ef20025361_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-015908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer